From initial FDA approvala
SINCE 2017, ≈253,000
PATIENTS HAVE FILLED AT
LEAST
1 DUPIXENT
PRESCRIPTIONb,c
a FDA approved since 2017 for adults, 2019 for adolescents (aged 12‑17 years), 2020 for children (aged 6-11 years),
and 2022 for infants to preschoolers (aged 6 months-5 years) with uncontrolled moderate‑to‑severe atopic dermatitis.
b IQVIA National Source of Business (NSOB) data as of April 2022.
c New adult and pediatric patients with uncontrolled moderate‑to‑severe atopic dermatitis.
It's Eczema
Awareness Month
Hear the stories
Get the stats
Take the Dx challenge
In uncontrolled moderate-to-severe
atopic dermatitis
DUPIXENT demonstrated rapid and sustained results in adults
and avoids broad immunosuppression1,2
- It is unknown if DUPIXENT will influence the immune response against helminth infections
Demonstrated safety profile in patients as young as 6 months of age1
Available in a 200 mg and 300 mg
pre-filled pen (for indicated patients 2+
years of age) or a pre-filled syringe
(for indicated patients 6+ months of age)
for subcutaneous injection1,3
One dose every 2 or 4 weeks based on age and weight (after an initial loading dose of two subcutaneous injections) in patients aged 6+ years. For patients aged 6 months to 5 years, one dose every 4 weeks based on weight, with no initial loading dose recommended1
Explore appropriate dosing schedules and weight-tiered regimens for DUPIXENT, which does not require initial lab testing or ongoing lab monitoring according to the Prescribing Information.1
DUPIXENT is available in a 200 mg and 300 mg pre-filled pen (for indicated patients 2+ years of age) or pre-filled syringe (for indicated patients 6+ months of age) for subcutaneous injection.1,2
Samples may be available—speak with your DUPIXENT representative for more information, or click here to contact a representative.
See DosAGE and Administration
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one ongoing support, and more.